Skip to main content
Signal8
Launch Terminal

Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Zentalis Pharmaceuticals, Inc. logo

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTLHealthcare
-1.51%$1.96
AH$1.96-0.02%vs close
Mkt Cap$192.34M
Float96.76M
O/S98.13M
Vol
$ Vol
RVOL
Inst Own48.0%
SI6.2%
Earnings
Dilution
Zentalis Pharmaceuticals, Inc. logoNASDAQ:ZNTL$1.96-1.51%
Upcoming Catalysts
  • azenosertibREADOUT
    Cash runway at this date: 12mo
    Oct 23, 202610d ago8-K
Phase Distribution
13 lead-sponsored trials·3 active·8 completed
Phase 17
Phase 1/23
Phase 22
Phase 31
(7 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Recruiting

    A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

    Investigator's choice of Chemotherapy, Azenosertib

    Ovarian Cancer

    Enrollment
    420
    Start
    Apr 2026
    Primary Completion
    May 2028est.
    Completion
    Apr 2030est.
    NCT07546500
  • Phase 2
    Completed

    A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

    Azenosertib

    Uterine Serous Carcinoma

    Enrollment
    92
    Start
    Jul 2021
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT04814108
  • Phase 2
    Recruiting

    A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    azenosertib

    High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    Enrollment
    310
    Start
    Feb 2022
    Primary Completion
    Dec 2026est.READOUT • Δ=15.9months median OS in Cyclin E1-positive PROC (vs 7.5 months in Cyclin E1-negative)
    Completion
    Jun 2027est.
    NCT05128825
  • Phase 1/2
    Completed

    A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

    Azenosertib, Niraparib

    Ovarian Cancer, Platinum-resistant Ovarian Cancer +2

    Enrollment
    117
    Start
    Jan 2022
    Primary Completion
    Oct 2025
    Completion
    Jan 2026
    NCT05198804
  • Phase 1/2
    Completed

    Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

    ZN-d5

    Amyloidosis, AL Amyloidosis

    Enrollment
    18
    Start
    Nov 2021
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05199337
  • Phase 1/2
    Terminated

    Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

    ZN-d5 ZN-c3, ZN-c3

    Acute Myeloid Leukemia (AML)

    Enrollment
    40
    Start
    Dec 2022
    Primary Completion
    Jul 2024
    Completion
    Jul 2024
    NCT05682170
  • Phase 1
    Completed

    A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

    ZN-e4

    Carcinoma, Non-Small-Cell Lung

    Enrollment
    34
    Start
    Apr 2018
    Primary Completion
    Jan 2022
    Completion
    Nov 2022
    NCT03446417
  • Phase 1
    Completed

    A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

    Azenosertib

    Solid Tumor

    Enrollment
    274
    Start
    Nov 2019
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT04158336
  • Phase 1
    Completed

    Phase 1 First in Human Study of ZN-d5 as a Single Agent

    ZN-d5

    Acute Myeloid Leukemia, Non Hodgkin Lymphoma

    Enrollment
    39
    Start
    Oct 2020
    Primary Completion
    Dec 2023
    Completion
    Dec 2023
    NCT04500587
  • Phase 1
    Recruiting

    A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

    Azenosertib, Carboplatin

    Solid Tumor, Epithelial Ovarian Cancer +2

    Enrollment
    172
    Start
    Oct 2020
    Primary Completion
    Jun 2028est.
    Completion
    Jun 2028est.
    NCT04516447
  • Phase 1
    Completed

    A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

    Azenosertib, Gemcitabine

    Osteosarcoma

    Enrollment
    31
    Start
    Aug 2021
    Primary Completion
    Aug 2023
    Completion
    Mar 2024
    NCT04833582
  • Phase 1
    Completed

    A Food Effect Study of ZN-d5 in Healthy Female Volunteers

    ZN-d5

    Healthy Volunteers

    Enrollment
    16
    Start
    Jun 2021
    Primary Completion
    Jun 2021
    Completion
    Jul 2021
    NCT04854174
  • Phase 1
    Terminated

    ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

    ZN-c3, Encorafenib

    Metastatic Colorectal Cancer

    Enrollment
    44
    Start
    Feb 2023
    Primary Completion
    Jul 2024
    Completion
    Jul 2025
    NCT05743036
Search ClinicalTrials.gov for “Zentalis Pharmaceuticals”